Track FDA investigations, drug approvals, disease outbreaks, and public health policy changes over time. Pingmer follows the regulatory and medical timeline and pings you when something shifts — a drug is approved, an outbreak spreads, or guidelines change.
The UK's PATHWAYS clinical trial for puberty blockers was paused on February 21, 2026, following concerns from the MHRA regarding participant wellbeing and a recommended minimum age of 14 due to potential long-term biological harms. As of March 1, 2026, Professor Jacob George, chief medical and scientific officer at the MHRA, was removed from further involvement in the trial due to accusations of bias, despite his social media posts predating his appointment. Discussions are ongoing between the MHRA and King's College London, the trial sponsor, with recruitment halted until issues are resolved. This pause follows legal challenges from campaigners and NHS England's 2024 decision to restrict puberty blockers to research settings.
Federal health authorities have reopened a multistate investigation into Salmonella contamination in moringa supplements, identifying 119 infections across 36 states and 32 hospitalizations. Total Nutrition Inc. and Mogo Moringa LLC have issued voluntary recalls of their moringa products as part of this renewed investigation.
As of April 28, 2026, the United States has confirmed 1,814 measles cases nationwide, the highest in two decades. The South Carolina outbreak, which began in October 2025, was officially declared over on April 28, 2026, after reporting 997 cases and 21 hospitalizations.
Видео от 15 марта 2026 года детализирует события в Прокопьевском психоневрологическом интернате, исследуя хронологию вспышки гриппа А, причины массовых смертей и реакцию властей. Расследование указало на преднамеренное бездействие как фактор, способствовавший трагедии.
Research is exploring solriamfetol, a wakefulness-promoting agent, which has shown promise in improving fatigue and executive functioning in adults with ME/CFS after eight weeks of treatment. This adds to existing research suggesting ketamine may offer rapid relief for chronic fatigue symptoms.
Early analyses from April 2026 indicate positive safety results for the tooth regeneration drug TRG-035, with no significant adverse effects reported in 30 healthy adult males participating in human trials at Kyoto University Hospital. Researchers remain hopeful for a potential drug release around 2030, pending the outcomes of ongoing and future trials.
A submission for approval of zoliflodacin in South Africa is planned for early 2026.
Actor Quinton Aaron has been discharged from the hospital and is now undergoing intensive physical therapy following a spinal stroke and cyst diagnosis. He was hospitalized in January 2026 and placed on life support.
A separate meningitis outbreak in Reading, Berkshire, has resulted in one student death and two hospitalizations, involving Meningitis B. Experts are now advocating for a nationwide MenB vaccine rollout for adolescents. The Kent outbreak has seen cases rise to 20, with two deaths and 11 hospitalizations.
New clinical trials are underway to evaluate personalized immunotherapy for pancreatic cancer (NCT07587827) and the performance of the urine-based Panuri test for pancreatic ductal adenocarcinoma (NCT07587866). Additionally, research has identified B7-H3 as a potential therapeutic target for pancreatic cancer, opening avenues for targeted therapies.
On May 28, 2026, the pan-RAS inhibitor daraxonrasib showed promising results at ASCO 2026, nearly doubling median overall survival for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) compared to standard chemotherapy. This development is considered the most significant advance in PDAC treatment in over a decade. Daraxonrasib targets all RAS-mutant proteins, including KRAS, which is prevalent in PDAC.
Tim Andrews, a recipient of a gene-edited pig kidney transplant in January 2025, has died after seven months. His transplanted kidney had been functioning, filtering waste and producing urine, before his death. This case is part of ongoing research into xenotransplantation to address organ shortages.
Drs. Kiran Musunuru and Rebecca Ahrens-Nicklas were recognized among TIME's 100 Most Influential People of 2026 for their pioneering work on personalized CRISPR gene therapy for CPS1 deficiency. This therapy, developed for infant KJ Muldoon, represents a historic milestone in treating rare genetic diseases.
The Countryside Alliance has declared the government's proposed consultation on aligning shotgun and firearms licensing a "existential and generational threat to shooting." This statement comes amid ongoing reviews and debates surrounding UK firearms licensing laws.
Eli Lilly announced that the FDA has granted fast-track designation to its VERVE-102 gene therapy for high cholesterol. The company plans to initiate Phase 2 studies by the end of 2026, following promising Phase 1b results showing significant and durable reductions in PCSK9 protein and LDL cholesterol levels.
The biological parents of the child have been identified as of April 2026, though their identities are being kept confidential. The couple suing the Fertility Center of Orlando will continue to parent the child, while the lawsuit remains open to address questions about their own embryos. The clinic is scheduled to close on May 20, 2026.
The World Health Organization has assessed the Nipah virus outbreak in West Bengal, India, classifying subnational risk as moderate and national, regional, and global risks as low. Several countries in the region, including Thailand, Nepal, Cambodia, Indonesia, and Malaysia, have initiated precautionary measures such as public information campaigns and passenger screenings.
The future of Mount Carmel Hospital is uncertain amid ongoing plans for the expansion of Mater Dei Hospital's emergency department and new mental health wards. This situation is linked to a controversial €120 million project.
Nurses in New York City have returned to work following the conclusion of a strike, as noted in the Federal Reserve Bank of New York's April 2026 Beige Book.
The FDA released a report on May 29, 2026, detailing its timeline and traceback findings in the botulism outbreak tied to ByHeart infant formula. The investigation suggests the product may have been contaminated long before the outbreak was identified.